A Hepatitis C Virus Infection Model with Time-Varying Drug Effectiveness: Solution and Analysis
Abstract
Simple models of therapy for viral diseases such as hepatitis C virus (HCV) or human immunodeficiency virus assume that, once therapy is started, the drug has a constant effectiveness. More realistic models have assumed either that the drug effectiveness depends on the drug concentration or that the effectiveness varies over time. Here a previously introduced varying-effectiveness (VE) model is studied mathematically in the context of HCV infection. We show that while the model is linear, it has no closed-form solution due to the time-varying nature of the effectiveness. We then show that the model can be transformed into a Bessel equation and derive an analytic solution in terms of modified Bessel functions, which are defined as infinite series, with time-varying arguments. Fitting the solution to data from HCV infected patients under therapy has yielded values for the parameters in the model. We show that for biologically realistic parameters, the predicted viral decay on therapy is generally biphasic and resembles that predicted by constant-effectiveness (CE) models. We introduce a general method for determining the time at which the transition between decay phases occurs based on calculating the point of maximum curvature of the viral decay curve. For the parameter regimes ofmore »
- Authors:
-
- Los Alamos National Lab. (LANL), Los Alamos, NM (United States)
- Publication Date:
- Research Org.:
- Los Alamos National Laboratory (LANL), Los Alamos, NM (United States)
- Sponsoring Org.:
- USDOE Office of Science (SC), Biological and Environmental Research (BER). Biological Systems Science Division; National Institutes of Health (NIH)
- OSTI Identifier:
- 1627237
- Grant/Contract Number:
- AC52-06NA25396; R01-OD011095; R01-AI078881; R34-HL109334; P20-GM103452; R01-AI028433
- Resource Type:
- Accepted Manuscript
- Journal Name:
- PLoS Computational Biology (Online)
- Additional Journal Information:
- Journal Name: PLoS Computational Biology (Online); Journal Volume: 10; Journal Issue: 8; Journal ID: ISSN 1553-7358
- Publisher:
- Public Library of Science
- Country of Publication:
- United States
- Language:
- English
- Subject:
- 59 BASIC BIOLOGICAL SCIENCES; Biochemistry & Molecular Biology; Mathematical & Computational Biology
Citation Formats
Conway, Jessica M., and Perelson, Alan S. A Hepatitis C Virus Infection Model with Time-Varying Drug Effectiveness: Solution and Analysis. United States: N. p., 2014.
Web. doi:10.1371/journal.pcbi.1003769.
Conway, Jessica M., & Perelson, Alan S. A Hepatitis C Virus Infection Model with Time-Varying Drug Effectiveness: Solution and Analysis. United States. https://doi.org/10.1371/journal.pcbi.1003769
Conway, Jessica M., and Perelson, Alan S. Thu .
"A Hepatitis C Virus Infection Model with Time-Varying Drug Effectiveness: Solution and Analysis". United States. https://doi.org/10.1371/journal.pcbi.1003769. https://www.osti.gov/servlets/purl/1627237.
@article{osti_1627237,
title = {A Hepatitis C Virus Infection Model with Time-Varying Drug Effectiveness: Solution and Analysis},
author = {Conway, Jessica M. and Perelson, Alan S.},
abstractNote = {Simple models of therapy for viral diseases such as hepatitis C virus (HCV) or human immunodeficiency virus assume that, once therapy is started, the drug has a constant effectiveness. More realistic models have assumed either that the drug effectiveness depends on the drug concentration or that the effectiveness varies over time. Here a previously introduced varying-effectiveness (VE) model is studied mathematically in the context of HCV infection. We show that while the model is linear, it has no closed-form solution due to the time-varying nature of the effectiveness. We then show that the model can be transformed into a Bessel equation and derive an analytic solution in terms of modified Bessel functions, which are defined as infinite series, with time-varying arguments. Fitting the solution to data from HCV infected patients under therapy has yielded values for the parameters in the model. We show that for biologically realistic parameters, the predicted viral decay on therapy is generally biphasic and resembles that predicted by constant-effectiveness (CE) models. We introduce a general method for determining the time at which the transition between decay phases occurs based on calculating the point of maximum curvature of the viral decay curve. For the parameter regimes of interest, we also find approximate solutions for the VE model and establish the asymptotic behavior of the system. We show that the rate of second phase decay is determined by the death rate of infected cells multiplied by the maximum effectiveness of therapy, whereas the rate of first phase decline depends on multiple parameters including the rate of increase of drug effectiveness with time.},
doi = {10.1371/journal.pcbi.1003769},
journal = {PLoS Computational Biology (Online)},
number = 8,
volume = 10,
place = {United States},
year = {Thu Aug 07 00:00:00 EDT 2014},
month = {Thu Aug 07 00:00:00 EDT 2014}
}
Works referenced in this record:
Antiviral therapy of hepatitis C in 2014: Do we need resistance testing?
journal, May 2014
- Schneider, Maximilian David; Sarrazin, Christoph
- Antiviral Research, Vol. 105
Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy
journal, June 1999
- Tsiang, Manuel; Rooney, James F.; Toole, John J.
- Hepatology, Vol. 29, Issue 6
On the exponential solution of differential equations for a linear operator
journal, November 1954
- Magnus, Wilhelm
- Communications on Pure and Applied Mathematics, Vol. 7, Issue 4
Modeling amantadine treatment of influenza A virus in vitro
journal, September 2008
- Beauchemin, Catherine A. A.; McSharry, James J.; Drusano, George L.
- Journal of Theoretical Biology, Vol. 254, Issue 2
Modelling viral and immune system dynamics
journal, January 2002
- Perelson, Alan S.
- Nature Reviews Immunology, Vol. 2, Issue 1
Silibinin mode(s) of action against hepatitis C virus: A controversy yet to be resolved
journal, June 2011
- Dahari, Harel; Guedj, Jeremie; Perelson, Alan S.
- Hepatology, Vol. 54, Issue 2
Modelling the kinetics of hepatitis C virus RNA decline over 4 weeks of treatment with pegylated interferon α-2b
journal, May 2008
- Shudo, E.; Ribeiro, R. M.; Perelson, A. S.
- Journal of Viral Hepatitis, Vol. 15, Issue 5
A Comprehensive Hepatitis C Viral Kinetic Model Explaining Cure
journal, May 2010
- Snoeck, E.; Chanu, P.; Lavielle, M.
- Clinical Pharmacology & Therapeutics, Vol. 87, Issue 6
Modeling HCV kinetics under therapy using PK and PD information
journal, March 2009
- Shudo, Emi; Ribeiro, Ruy M.; Perelson, Alan S.
- Expert Opinion on Drug Metabolism & Toxicology, Vol. 5, Issue 3
Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon- Therapy
journal, October 1998
- Neumann, A. U.
- Science, Vol. 282, Issue 5386
Modelling how ribavirin improves interferon response rates in hepatitis C virus infection
journal, December 2004
- Dixit, Narendra M.; Layden-Almer, Jennifer E.; Layden, Thomas J.
- Nature, Vol. 432, Issue 7019
Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: Implications for treatment duration
journal, May 2011
- Guedj, Jeremie; Perelson, Alan S.
- Hepatology, Vol. 53, Issue 6
Modeling Viral and Drug Kinetics: Hepatitis C Virus Treatment with Pegylated Interferon Alfa-2b
journal, January 2003
- ,
- Seminars in Liver Disease, Vol. 23
Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life
journal, February 2013
- Guedj, J.; Dahari, H.; Rong, L.
- Proceedings of the National Academy of Sciences, Vol. 110, Issue 10
Mathematical Analysis of HIV-1 Dynamics in Vivo
journal, January 1999
- Perelson, Alan S.; Nelson, Patrick W.
- SIAM Review, Vol. 41, Issue 1
Analysis of Hepatitis C Virus Decline during Treatment with the Protease Inhibitor Danoprevir Using a Multiscale Model
journal, March 2013
- Rong, Libin; Guedj, Jeremie; Dahari, Harel
- PLoS Computational Biology, Vol. 9, Issue 3
Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics
journal, December 2010
- Guedj, J.; Neumann, A. U.
- Journal of Theoretical Biology, Vol. 267, Issue 3
Rapid Emergence of Protease Inhibitor Resistance in Hepatitis C Virus
journal, May 2010
- Rong, L.; Dahari, H.; Ribeiro, R. M.
- Science Translational Medicine, Vol. 2, Issue 30
Modelling hepatitis C virus kinetics during treatment with pegylated interferon α-2b: errors in the estimation of viral kinetic parameters
journal, May 2008
- Shudo, E.; Ribeiro, R. M.; Perelson, A. S.
- Journal of Viral Hepatitis, Vol. 15, Issue 5
Characterization of the Metabolic Activation of Hepatitis C Virus Nucleoside Inhibitor β-d-2′-Deoxy-2′-fluoro-2′-C-methylcytidine (PSI-6130) and Identification of a Novel Active 5′-Triphosphate Species
journal, October 2007
- Ma, Han; Jiang, Wen-Rong; Robledo, Nicole
- Journal of Biological Chemistry, Vol. 282, Issue 41
Analysis of hepatitis B viral load decline under potent therapy: Complex decay profiles observed
journal, November 2001
- Lewin, S.
- Hepatology, Vol. 34, Issue 5
The Magnus expansion and some of its applications
journal, January 2009
- Blanes, S.; Casas, F.; Oteo, J. A.
- Physics Reports, Vol. 470, Issue 5-6
Complex patterns of viral load decay under antiretroviral therapy: influence of pharmacokinetics and intracellular delay
journal, January 2004
- Dixit, Narendra M.; Perelson, Alan S.
- Journal of Theoretical Biology, Vol. 226, Issue 1
Severity of liver disease affects HCV kinetics in patients treated with intravenous silibinin monotherapy
journal, January 2014
- Canini, Laetitia; DebRoy, Swati; Mariño, Zoe
- Antiviral Therapy, Vol. 20, Issue 2
Kinetics of Influenza A Virus Infection in Humans
journal, July 2006
- Baccam, P.; Beauchemin, C.; Macken, C. A.
- Journal of Virology, Vol. 80, Issue 15
Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128)
journal, February 2012
- Guedj, Jeremie; Dahari, Harel; Shudo, Emi
- Hepatology, Vol. 55, Issue 4
Pharmacodynamics of PEG-IFN α differentiate HIV/HCV coinfected sustained virological responders from nonresponders
journal, May 2006
- Talal, Andrew H.; Ribeiro, Ruy M.; Powers, Kimberly A.
- Hepatology, Vol. 43, Issue 5
Understanding silibinin’s modes of action against HCV using viral kinetic modeling
journal, May 2012
- Guedj, Jeremie; Dahari, Harel; Pohl, Ralf T.
- Journal of Hepatology, Vol. 56, Issue 5
Modeling complex decay profiles of hepatitis B virus during antiviral therapy
journal, August 2008
- Dahari, Harel; Shudo, Emi; Ribeiro, Ruy M.
- Hepatology, Vol. 49, Issue 1
Primer unblocking by HIV-1 reverse transcriptase and resistance to nucleoside RT inhibitors (NRTIs)
journal, September 2004
- Goldschmidt, V.
- The International Journal of Biochemistry & Cell Biology, Vol. 36, Issue 9
Pharmacodynamics of PEG-IFN-α-2a in HIV/HCV co-infected patients: Implications for treatment outcomes
journal, September 2010
- Dahari, Harel; Affonso de Araujo, Evaldo S.; Haagmans, Bart L.
- Journal of Hepatology, Vol. 53, Issue 3
Pharmacodynamics of PEG-IFN α differentiate HIV/HCV coinfected sustained virological responders from nonresponders
journal, May 2006
- Talal, Andrew H.; Ribeiro, Ruy M.; Powers, Kimberly A.
- Hepatology, Vol. 43, Issue 5
Modeling complex decay profiles of hepatitis B virus during antiviral therapy
journal, August 2008
- Dahari, Harel; Shudo, Emi; Ribeiro, Ruy M.
- Hepatology, Vol. 49, Issue 1
Multiple effects of silymarin on the hepatitis C virus lifecycle
journal, February 2010
- Wagoner, Jessica; Negash, Amina; Kane, Olivia J.
- Hepatology, Vol. 51, Issue 6
Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: Implications for treatment duration
journal, May 2011
- Guedj, Jeremie; Perelson, Alan S.
- Hepatology, Vol. 53, Issue 6
Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128)
journal, February 2012
- Guedj, Jeremie; Dahari, Harel; Shudo, Emi
- Hepatology, Vol. 55, Issue 4
Antiviral therapy of hepatitis C in 2014: Do we need resistance testing?
journal, May 2014
- Schneider, Maximilian David; Sarrazin, Christoph
- Antiviral Research, Vol. 105
Primer unblocking by HIV-1 reverse transcriptase and resistance to nucleoside RT inhibitors (NRTIs)
journal, September 2004
- Goldschmidt, V.
- The International Journal of Biochemistry & Cell Biology, Vol. 36, Issue 9
Mathematical modeling: A tool for selecting agents with complementary modes of action?
journal, December 2013
- Deuffic-Burban, Sylvie; Yazdanpanah, Yazdan
- Journal of Hepatology, Vol. 59, Issue 6
Complex patterns of viral load decay under antiretroviral therapy: influence of pharmacokinetics and intracellular delay
journal, January 2004
- Dixit, Narendra M.; Perelson, Alan S.
- Journal of Theoretical Biology, Vol. 226, Issue 1
Modelling how ribavirin improves interferon response rates in hepatitis C virus infection
journal, December 2004
- Dixit, Narendra M.; Layden-Almer, Jennifer E.; Layden, Thomas J.
- Nature, Vol. 432, Issue 7019
Modelling viral and immune system dynamics
journal, January 2002
- Perelson, Alan S.
- Nature Reviews Immunology, Vol. 2, Issue 1
Twice-weekly pegylated interferon-α-2a and ribavirin results in superior viral kinetics in HIV/hepatitis C virus co-infected patients compared to standard therapy
journal, January 2011
- Murphy, Alison A.; Herrmann, Eva; Osinusi, Anu O.
- AIDS, Vol. 25, Issue 9
Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon- Therapy
journal, October 1998
- Neumann, A. U.
- Science, Vol. 282, Issue 5386
Analysis of the hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938
journal, January 2014
- Guedj, Jeremie; Pang, Phillip S.; Denning, Jill
- Antiviral Therapy, Vol. 19, Issue 2
Works referencing / citing this record:
Cancer-induced immunosuppression can enable effectiveness of immunotherapy through bistability generation : a mathematical and computational examination
text, January 2020
- Garcia, Victor; Bonhoeffer, Sebastian; Fu, Feng
- Elsevier
Cancer-Induced Immunosuppression can enable Effectiveness of Immunotherapy through Bistability Generation: a mathematical and computational Examination
journal, January 2020
- Garcia, Victor; Bonhoeffer, Sebastian; Fu, Feng
- Journal of Theoretical Biology
Cancer-induced immunosuppression can enable effectiveness of immunotherapy through bistability generation: a mathematical and computational examination.
text, January 2020
- Garcia, Victor; Bonhoeffer, Sebastian; Fu, Feng
- Elsevier
Interferon at the cellular, individual, and population level in hepatitis C virus infection: Its role in the interferon-free treatment era
journal, August 2018
- Raja, Rubesh; Baral, Subhasish; Dixit, Narendra M.
- Immunological Reviews, Vol. 285, Issue 1